Precemtabart tocentecan not checked

EMD Serono Research & Development Institute, Inc. · M9140

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
6 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
How it’s given
“Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle.”In the company’s words, NCT07549412 on ClinicalTrials.gov
Tested for
Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer
Main trialPhase 3
“This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluridine/tipiracil (FTD-TPI) plus bevacizumab.”In the company’s words, NCT07549412 on ClinicalTrials.gov
Other names
M9140 · Precem-TcT

Other drugs for Metastatic Colorectal Cancer

All 392 drugs for Metastatic Colorectal Cancer

Coming up2

Changes2

Last 90 days

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 16 Oct 2029 A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Phase 1/2Active, not recruiting 23 Dec 2027 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1Active, not recruiting 23 Oct 2026 Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Phase 1Completed 23 Sep 2026 Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
Phase 1/2Authorised not given PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC)
Phase 1/2Authorised not given PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Pancreatic Cancer (Substudy PDAC)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Precemtabart tocentecan

Following is part of Solo: you see every change to Precemtabart tocentecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in